Codman Neuro, a part of DePuy Synthes Companies of Johnson & Johnson, has signed a distribution agreement with Pulsar Vascular to market and promote its minimally invasive device PulseRider in Europe, Middle East and Africa (EMEA).
PulseRider is intended for use in conjunction with embolic coils to treat unruptured wide-neck intracranial aneurysms originating on or near a bifurcation.
The agreement was signed by one of Codman Neuro’s affiliated companies in the European Union (EU), and marks the latest expansion of the company’s neurovascular portfolio.
The self-expanding nitinol implant PulseRider, received initial CE Mark approval in Europe in late 2013.
Codman Neuro’s neurovascular portfolio includes a wide range of products for hemorrhagic and ischemic stroke, cerebral aneurysms and other neurovascular and neurological diseases and conditions.
Codman Neuro worldwide president Laxmin Laxminarain said: "We are excited about this new agreement with Pulsar Vascular and the greater access physicians and their patients in Europe will now have to a potentially lifesaving endovascular procedure.
"There is a significant unmet clinical need in the treatment of unruptured, wide-neck bifurcation aneurysms, and we hope to help fill it with this innovative device."
Cerebral aneurysms claims around 500,000 lives a year worldwide, with half the victims younger than 50 years, according to the Brain Aneurysm Foundation.
Paracelsus Medical University Salzburg professor Monika Killer-Oberpfalzer said: "Repairing wide-neck intracranial aneurysms is a challenging endovascular procedure and treatment options are extremely limited.
"We welcome technology specifically designed to enhance our ability to treat these complex aneurysms more easily with less risk in the hope that more lives can be saved."
In the US, PulseRider is limited to investigational use only and the device has not been approved for distribution by the US Food and Drug Administration (FDA).